Le Lézard
Classified in: Science and technology
Subject: TDS

Lucd Enterprise AI Announces a New 3D Immersive Technology at Gartner Symposium/ ITxpo 2018


NASHVILLE, Tenn. and ORLANDO, Fla., Oct. 16, 2018 /PRNewswire/ -- Lucd, a provider of an end to end Enterprise AI Platform announced the new Lucd Unity Interface for the Lucd Enterprise AI Platform providing innovators with an intuitive, immersive experience to explore and transform data for AI modeling from Gartner Symposium/ITxpo 2018.

Lucd provides the Enterprise with new AI driven business opportunities through the responsible use of data. Utilizing unique intellectual property combined with leading open source tools into an easy to use platform, Lucd enables all businesses to take advantage of the fast-moving AI market to gain a competitive advantage.

"At Lucd we are excited to be defining where AI can go. With Lucd Unity, we provide an immersive user experience that provides innovators and non-AI practitioners with an immersive experience to explore and transform data for AI modeling. Leveraging the Unity gaming engine, we provide a stunning cinematic, 3D experience for Enterprise AI outcomes across the Enterprise," said Dave Bauer, Ph.D., CTO and co-founder at Lucd.

In the December 2017 Report, Predicts 2018: Immersive Technologies and Devices Will Transform Personal and Business Interactions, Gartner states: "Users' expectations will increasingly shift from a 2D world to more immersive 3D interfaces, from using 3D to capture richer, friction-free input, to using 3D to present new experiences." In that paper, Gartner goes on to state: "By 2022, 20% of early adopters will use 3D input/output interfaces to replace traditional 2D/flat interactions."

About Lucd     

By unleashing the power of data, the Lucd Enterprise end to end AI platform allows all businesses to do new things responsibly. Lucd builds Competitive Digital Advantage through leveraging data assets; Digi- tal ROI; and providing the ability to exploit market knowledge. Lucd develops pioneering capabilities in AI, Big Data, Data Fusion and Machine Learning. Visit Lucd https://www.lucd.ai/

About Gartner Symposium/ITxpo    

Gartner Symposium/ITxpo is the world's most important gathering of CIOs and senior IT executives. This event delivers independent and objective content with the authority and weight of the world's leading IT research and advisory organization, and provides access to the latest solutions from key technology providers. CIOs and IT executives rely on Gartner Symposium/ITxpo to gain insight into how their organizations can use IT to address business challenges and improve operational efficiency. For more information, please visit www.gartner.com/us/symposium.

Photos:
https://www.prlog.org/12735190    

Press release distributed by PRLog

 

SOURCE Lucd


These press releases may also interest you

at 21:30
Rubrik, Inc. today announced the pricing of its upsized initial public offering of 23,500,000 shares of its Class A common stock at a public offering price of $32.00 per share. In addition, Rubrik has granted the underwriters a 30-day option to...

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:26
OKX, a leading Web3 technology company, has issued updates for April 24, 2024. OKX DeFi Launches 'zkSwap Bonus Event' Offering Users...

at 21:19
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on July 1, 2024 to shareholders of record at the close of business on June 1, 2024. The Board of Directors also declared the following...

at 21:02
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...



News published on and distributed by: